The launch of eight adalimumab biosimilars so far this year ended Humira s 20-year monopoly, but it s not clear yet if these discounted drugs will save patients money.
A long-term study of children with juvenile idiopathic arthritis highlights an inconsistent classification system and hints about how they manage their disease as they transition into adulthood.